» Articles » PMID: 36644035

Musculoskeletal System and Connective Tissue Related Hospital Admission in England and Wales Between 1999 and 2019: An Ecologic Study

Abstract

Background There is a lack of data describing inpatient hospitalization trends for musculoskeletal and connective tissue diseases in the United Kingdom. Aim We aim to provide a comprehensive analysis of the trends of musculoskeletal and connective tissue disease related hospitalizations between 1999 and 2019 in England and Wales. Method We conducted an ecologic study. The data were obtained from the Hospital Episode Statistics database in England and the Patient Episode Database in Wales between 1999 and 2019. We used ICD-10 (International Classification of Diseases, 10th Revision) codes M00-M99 to identify hospital admissions. Results The total annual hospital admission rate increased from 1,303.63 (95% CI: 1,300.55-1,306.71) in 1999 to 2,479.09 (95% CI: 2,475.14-2,483.04) in 2019 per 100,000 persons (p<0.01). The ICD-10 categories other joint disorders, osteoarthritis, and other dorsopathies accounted for 19.6%, 19.6%, and 18.6% of hospitalizations, respectively. Advanced age groups experienced a larger increase in hospitalization rates (128.6% in the age group of 75 years and above vs. 45.9% in the age group below 15 years). Females contributed to 57.7% of hospitalizations and experienced a larger increase in hospitalization rate compared to males (103.8% vs. 73.8%). Conclusion Between 1999 and 2009, the hospitalization rate for musculoskeletal and connective tissue diseases has steadily increased in England and Wales. However, the rate has plateaued or declined in many of musculoskeletal and connective tissue diseases between 2010 and 2019. Due to the chronicity of these diseases, their significant morbidity, and significant long-term disability, national interventions are needed to mitigate the effects of the increased cost of treatment.

Citing Articles

Insights into hospitalization pattern for drug, medicament, and biological substance poisoning, adverse effect, and underdosing in Australia: An ecological study between 1998 and 2019.

Naser A PLoS One. 2024; 19(8):e0309362.

PMID: 39208193 PMC: 11361606. DOI: 10.1371/journal.pone.0309362.


Postprocedural Complications Hospitalization Pattern Among Paediatric Patients at National Health Service Trusts: An Ecological Study in England and Wales.

Naser A, Al-Shehri H J Multidiscip Healthc. 2023; 16:3545-3554.

PMID: 38024128 PMC: 10661900. DOI: 10.2147/JMDH.S441247.


Postprocedural Disorders of Eye and Adnexa Admissions Profile.

Naqeeb M, Naser A Clin Optom (Auckl). 2023; 15:261-270.

PMID: 37937276 PMC: 10627053. DOI: 10.2147/OPTO.S437044.


Hospital Admission Profile Due to Osteoarthritis: An Ecological Study.

Ekram R, Nazer M Cureus. 2023; 15(5):e38435.

PMID: 37273367 PMC: 10234140. DOI: 10.7759/cureus.38435.


Admissions Due to Perinatal Respiratory and Cardiovascular Disorders in England.

Naser A, Al-Shehri H J Multidiscip Healthc. 2023; 16:199-207.

PMID: 36714239 PMC: 9879026. DOI: 10.2147/JMDH.S396406.


References
1.
Naser A, Alwafi H, Hemmo S, Alrawashdeh H, Alqahtani J, Alghamdi S . Trends in Hospital Admissions Due to Neoplasms in England and Wales between 1999 and 2019: An Ecological Study. Int J Environ Res Public Health. 2022; 19(13). PMC: 9265694. DOI: 10.3390/ijerph19138054. View

2.
Burmester G, Bijlsma J, Cutolo M, McInnes I . Managing rheumatic and musculoskeletal diseases - past, present and future. Nat Rev Rheumatol. 2017; 13(7):443-448. DOI: 10.1038/nrrheum.2017.95. View

3.
Hart J . On ecological studies: a short communication. Dose Response. 2012; 9(4):497-501. PMC: 3315170. DOI: 10.2203/dose-response.10-046.Hart. View

4.
Hemmo S, Naser A, Alwafi H, Mansour M, Alanazi A, Jalal Z . Hospital Admissions Due to Ischemic Heart Diseases and Prescriptions of Cardiovascular Diseases Medications in England and Wales in the Past Two Decades. Int J Environ Res Public Health. 2021; 18(13). PMC: 8297245. DOI: 10.3390/ijerph18137041. View

5.
Isaacs J, Burmester G . Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs. Ann Rheum Dis. 2020; 79(8):991-993. PMC: 7392482. DOI: 10.1136/annrheumdis-2020-218019. View